Riskpilot← Back to searchSign inGet full accessMedisera Aktiebolag
ABActiveOrg 5562957984Lodgatan 18Research and experimental development on natural sciences and engineering · NACE 7210Est. 19871 employees
Revenue 2025
SEK 421K
-3% vs 2024
EBITDA margin
62.2%
-26% vs 2024
Equity ratio
60.0%
Financial strength
Net profit 2025
SEK 201K
-16% vs 2024
| Revenue | SEK 421K | -3% |
| EBITDA | SEK 262K | -26% |
| Net profit | SEK 201K | -16% |
| Total assets | SEK 905K | +11% |
| Equity | SEK 544K | +13% |
| Employees | 1 | — |
Legal name
Medisera Aktiebolag
Org number
5562957984
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
13 april 1987
Share capital
SEK 100 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget skall bedriva utveckling, produktion och marknadsföring av biotekniska produkter samt konsultverksamhet inom detta område och därmed förenlig verksamhet. Vidare skall bolaget bedriva handel med och förvaltning av värdepapper och därmed förenlig verksamhet.
Address
Lodgatan 18
Phone
+4631836944
Email
rebecca@medisera.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 396 | 400 | 417 | 434 | 421 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 285 | 323 | 304 | 352 | 262 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 285 | 323 | 304 | 352 | 262 |
| Net financials | — | −4 | 3 | 4 | 0 |
| Profit before tax | 326 | 320 | 230 | 281 | 242 |
| Tax | −68 | −67 | −33 | −43 | −41 |
| Net profit | 258 | 253 | 197 | 238 | 201 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 669 | 657 | 699 | 815 | 905 |
| Equity | 442 | 383 | 365 | 483 | 544 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 96 | 144 | 127 | 50 | 60 |
| Total debt | 96 | 144 | 127 | 50 | 60 |
EBITDA margin
62.2%
This company
15.8%
Market median
+294% vs market
20212025
Equity ratio
60.0%
This company
38.2%
Market median
+57% vs market
20212025
Return on equity
37.0%
This company
18.4%
Market median
+101% vs market
20212025
Net profit margin
47.7%
This company
8.1%
Market median
+489% vs market
20212025
Asset turnover
0.47×
This company
1.12×
Market median
-58% vs market
20212025
Debt / equity
0.67×
This company
0.62×
Market median
+8% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
IB Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2025 | |
| Former (2) | ||
| Deputy Board Member | 2022 – 2025 | |
| Chairman | 2022 – 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Medisera Aktiebolag also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| I B Rebecca V Engelbert | Chief Executive Officer | 0 companies |
| Marcus Haglid | Deputy Board Member | 0 companies |
| Tomas Axel Setterberg | Deputy Board Member | 0 companies |
| Ing-Britt M Jallinder Haglid | Chairman | 0 companies |